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PP-128 Polysaccharopeptide stimulated human
peripheral blood mononuclear cells activation
and promoted anti-hepatitis B virus effect
in vitro
L. Xu1 *, L. Lin1, H.L. Wang1, Q. Wang1, G.M. Chen2, Y. Liu3,
C. Wu1. 1Department of Infectious Diseases, Nanjing Drum
Tower Hospital of Nanjing University Medical School,
2Department of Infectious Diseases, Jiangsu Province
Hospital of TCM, 3Department of Laboratory Medicine,
Nanjing Drum Tower Hospital of Nanjing University Medical
School, China
Background: The mechanism of anti-hepatitis B virus effects
of PSP is unclear.
Methods: Human peripheral blood mononuclear Cells
(PBMCs) obtained from healthy volunteer were co-cultured
with PSP. The ratio of CD4+/CD8+ and the expression of
CD3+HLA-DR+ and CD19+CD69+ of PBMCs were assessed
by ﬂow cytometry at 72 hours, meanwhile, detecting the
levels of IFN-g, IL-12 and IgG in supernatant by ELISA. Then
HepG2.2.15 cells were divided into four groups (Table 1).
HBVDNA load and the levels of HBsAg and HBeAg in
supernatant were detected by ﬂuorescent-quantitative PCR
and Abbott-chemiluminescent microparticle immunoassay
respectively at 96 h.
Results: At 72h, the ratio of CD4+/CD8+ in PBMCs+PSP
group was signiﬁcantly higher than PBMCs group (p < 0.05),
and, the expression of CD3+/HLA-DR+ and CD19+/CD69+ in
PBMCs+PSP group were higher than PBMCs group, however,
have no statistical signiﬁcance. PSP could increase IFN-g,
IL-12 and IgG (Graph 1). PSP couldn’t inhibit HBV replication
directly; PBMCs activated by PSP reduced HBsAg and
HBeAg secretion signiﬁcantly, however, have no remarkable
inhibitory effects of HBVDNA (Table 1).
Graph 1. Effect of PSP on IFN-g, IL-12 and IgG secretion by
PBMCs at 72 h (n = 7).
Table 1. Effect of PBMCs activated by PSP on HBsAg, HBeAg and HBV DNA
at 96 h (X±s)
HBsAg HBeAg HBV-DNA
Level
(IU/ml)
Inhibition
rate
Level (S/CO) Inhibition
rate
Inhibition
rate
Treatment group:
(PBMCs co-cultured
with PSP + HepG2.2.15
cells)
4.13±0.92** 50.63%** 24.89±13.67 55.05% 4.78%
Un-treated group:
(PBMCs cultured
without PSP +
HepG2.2.15 cells)
5.86±1.32* 29.40%* 33.29±19.29 39.26% 2.87%
PSP group:
PSP + HepG2.2.15 cells
8.64±1.09 2.88% 50.24±19.99 1.73* 12.28%
Control group:
HepG2.2.15 cells
8.41±0.66 51.67±21.51
Conclusion: The PSP could activate T and B lymphocytes
and increased IFN-g and IL-12 levels of PBMCs, The effect
of HBsAg and HBeAg inhibition owe to the immune response
of PBMCs activated by PSP.
PP-129 Clinical picture of acute viral hepatitis A in
Mongolian children with HBsAg
J. Ulaan1, D. Tungalag2, Y. Dahgwahdorj2 *. 1Center of
Communicable Diseases of Mongolia, 2Health Science
University of Mongolia, Mongolia
Background: HBV infection is endemic in Mongolia.
So, Mongolian Government launched HBV vaccination as
mandatory immunization since 1991. After that, the
incidence acute viral hepatitis and mortality from acute
liver failure were dramatically decreased. But, it was
not stopped concurrent acute viral hepatitis A and B in
practice.
Purpose of study: To study the clinical picture of acute
viral hepatitis A in children with HBsAg.
Material and Method: In this study, we selected 130 children
(age 1 15; male 84) with acute icteric viral hepatitis, whom
positive detected HBsAg. In 102 children detected only anti-
HA-IgM (1st group), in 8 also anti-HAV-IgM and anti-HBc-IgM
(2nd group) in 20 detected anti-HBc-IgM but not anti-HAV-IgM
(3rd group). Study was conducted at Communicable Diseases
Centre of Mongolia in 2005 2009.
Results: In children for 1st group were severe form 7.8%;
moderate severe form 23.5% cases, then in 2nd group were
severe form 50.0%; moderate severe form were 12.5%; in
3rd group were fulminant form 25.0%, severe form 25.0%
and moderate severe form were 15.0%; There was case
of fulminant liver failure only in acute HBV infection. The
course of clinic manifestations were depending on study
groups shown in the table.
Study groups 1st group
HBsAg(+),
anti-HAV-IgM(+)
anti-HBc-IgM( )
2nd group
HBsAg(+),
anti-HAV-IgM(+)
anti-HBc-IgM(+)
3rd group
HBsAg(+),
anti-HAV-IgM( )
anti-HBc-IgM(+)
Prolongation of intoxication 4 days 6 days 7 days
Prolongation of jaundice 7 days 11 days 12 days
Normalization of GPT 20.2 days 24.6 days 33.4 days
Conclusion: The course of acute Icteric viral hepatitis A in
children with HBsAg predominantly mild as HAV infection.
PP-130 Development and application of Reverse Dot
Blot (RDB) hybridization assay for HBV Pol/RT
resistant mutation
Y.L. Zeng1 *, Y.P. Zhou1, T.S. Zhang2, H.T. He1, W.F. Liang1,
H.H. Huang1, J.F. Wei1, Y.J. Wang1, J.L. Hou1. 1Hepatology
Unit and Department of Infectious Diseases, Nanfang
Hospital, Southern Medical University, Guangzhou 510515,
China, 2Da An Gene Co., Ltd. of Sun Yat-sen University,
China
Objectives: The purpose of this study was to develop a
method for detecting the mutations at YMDD by reverse dot
blot (RDB) hybridization assay, which was speciﬁc, sensitive
and simple.
Methods: Using LiPA technology principle, we designed
a groups of capture probes with PolyT tail, ﬁxed on
the NC membrane and developed the method Reverse
Dot Blot (RDB) hybridization assay. Sera were collected
from patients with hepatitis B who were predicted to
develop viral breakthrough during lamivudine treatment at
infectious department of NanFang Hospital, between 2006
and 2007. For 134 samples with YMDD mutantion detected by
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PCR restriction-fragment-length-polymorphism (PCR-RFLP)
assay, we determined them by RDB hybridization assay
again and the samples were sequenced directly in cases
with inconsistent results. 40 samples with consistent results
were randomly selected and sequenced directly.
Results: 36 samples were inconsistent with each other by
RDB hybridization assay and PCR-RFLP. Since no products
could get by PCR, 14 (14/36) samples with inconsistent
results could not be sequenced. Total of 62 samples were
sequenced (the rest 22 samples with inconsistent results
and 40 samples randomly selected), whose coincidence rate
was 96.77% (60/62), compared to RDB hybridization assay.
Combined result of sequencing, coincidence rate of RDB
hybridization assay was signiﬁcantly higher compared to
that of PCR-RFLP (X2 = 16.4, P< 0.05).
Conclusions: The RDB hybridization assay we established
could identify YMDD mutation in a single assay with
reliability and speciﬁcity, and especially had the superiority
of high speciﬁcity for mixed infection. Furthermore, the
results were easier to be judged by eyes directly. RDB
hybridization assay was a better method for mixed infection
of HBV YMDD motif than PCR-RFLP and DNA direct
sequencing. It has a great potential of application because
of making operation even more simple and cost-savings.
PP-131 PCR product pyrosequencing for detecting HBV
resistance to adefovir
S. Yang1 *, J.M. Zheng1, X.Y. Wang1, Q. Wang1, H.C. Xing1,
W. Xie1, J. Cheng1. 1Beijing Ditan Hospital, Capital Medical
University, China
Objective: To evaluate PCR product pyrosequencing in
detecting genotypic resistance of adefovir in chronic
hepatitis B (CHB) patients.
Methods: Serum and clinical data of CHB patients who
had taken ADV mono-therapy were collected, they were
once underwent viral breakthrough or could not achieve
virological response after at least 48 weeks therapy. ADV
associated mutations including rtA181V/T and rtN236T
were detected by pyrosequencing. Resistance and ratio of
mutants were analyzed with software of sequencer. PCR
product di-deoxy sequencing was also used for analysis of
ADV resistance. And resistantce proﬁles get from two assays
were compared.
Results: 210 CHB patients were tested. Totally 67
ADV resistance patients and 92 mutants were detected.
64 patients were positive for ADV resistance by
pyrosequencing, and 52 cases by di-deoxy sequencing, the
coincidence of the two approaches was 83.8%. there were
44 patients who had single mutants, 26 of them had a ratio
of mutants <50%.
Conclusions: Pyrosequencing is effective in detecting
adefovir resistance. Adefovir resistance mutant clones may
not be the dominant in the population even in breakthrough
patients.
Table 1. Pyrosequencing and di-deoxy sequencing for detecting adefovir
resistance
Mutation Pyrosequencing Di-deoxy sequencing
rtA181T 26 19
rtA181V 11 12
rtN236T 7 2
rtA181V/T 1 1
rtA181T+rtN236T 9 10
rtA181V+rtN236T 8 8
rtA181V/T+rtN236T 2 0
Total 64 52
PP-132 Modeling adefovir dipivoxil anti-HBV infection
treatment
L.Q. Min1 *, P.F. Zhang1, Y.J. Li1, L. Meng1, J. Zhang2,
L. Zhou2, B. Zhang2. 1Applied Science School, University
of Science and Technology Beijing, Beijing, 100083, China,
2Capital Medical University, Beijing Youan Hospital, Beijing
100069, China
Background and Objectives: Adefovir dipivoxil (AD) can
make over 20% HBeAg-positive chronic hepatitis B (CHB)
patients’ HBVDNA loads be reduced to undetectable levels
after one years treatment. Many CHB patients’ HBVDNA
relapsed after stopping therapy. The selection of durations
and endpoints of treatment is important and difﬁcult issues.
This study evaluates duration treatment time via modeling
the dynamics of AD anti-HBV infection therapy.
Methods: A total of 39 HBeAg-positive CHB patients with
baseline HBVDNA >105 copies/mL and ALT >2ULN received
AD (10mg/day) in a multicenter, randomized, double-
blind study. Patients were treated for 96 weeks. Using a
differential equation model (L. Min et al., in Proc. IASTED
Int. Conf. Modelling, Simulation, and Identiﬁcation 2009,
659 057) simulated the course of patients HBVDNA levels.
Results: At the endpoint, about 23% (9/39) patients had
HBVDNA <250 cp/mL (the detection lower limit) and
ALT became normalization. About 38% (15/39) patients’s
HBVDNA levels were breakthrough. About 38% (15/39)
patients’ HBVDNA levels were not reduced to be less
250cp/mL. Simulated the course of HBVDNA for 4 patients
who had high baseline HBVDNA (>107 cp/mL) and HBVDNA
<250cp/mL at the endpoint. Results shown that the
simulated data of our models were agrement with in the
experimental ones. The simulations shown that it needed
about 18 years to replace the patients infected hepatocytes
by normal ones.
Conclusion: For high baseline HBVDNA level CHB patients,
AD may not be an idea monotone ﬁrst line anti-HBV infection
therapy drug. Entecavir may be a more promising candidate
to treat such kind of CHB patients.
Acknowledgments: This work is supported by the Yong
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PP-133 Molecular study of HCV detection, genotypes
and their routes of transmission in North West
Frontier Province (N.W.F.P.) of Pakistan
S. Zaman Saﬁ1 *, I. Qadri1. 1NUST Center of Virology and
immunology, National University of Science and Technology,
Pakistan
Very little is known about the epidemiological
manifestation, genotypes and risk factors of HCV infection
in North West Frontier Province (N.W.F.P) of Pakistan.
Therefore, the subject study was conducted to determine
HCV genotypes and to explore the associated risk factors
in chronic HCV patients. 116 chronic HCV patients were
enrolled for qualitative analysis by PCR out of which 112
chronic HCV patients (53, 47.32% males and 59, 52.68%
females) with mean age 43.76±16.4 and mean BMI 23.8±3.9
were included in this study. Frequency of six HCV genotypes
and associated risk factors were evaluated from ﬁve districts
of N.W.F.P.
Genotype 3 was the most prevalent in 73 samples (65.17%)
followed by genotype 1 in 24 (21.42%) and genotype 2
in 13 (11.60%) samples. Genotype 3 has signiﬁcantly high
prevalence (P= 0.0002). 48 (42.85%) samples were proved
as HCV 3a; 25 (22.32%) 3b; 14 (12.5%) 1a; 10 (08.92%) 1b; 11
(09.82%) 2a; 2 (1.78%) 2b and 2 Untypable. HCV genotype
3a, 3b, 2a, 1a, 1b were most prevalent in Nowshehra,
Peshawar, Mardan, Sawabi and Mardan respectively. HCV
